Lymphovenous Bypass Procedure for Secondary Prevention of Lymphedema in Breast Cancer
Recruiting · NCT07233863 · Interventional (participants receive a specific treatment) · Lead sponsor: Dharmais National Cancer Center Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Lymphovenous bypass (LVB)
What this trial is about
This study aims to evaluate the effectiveness of the Lymphovenous Bypass (LVB) procedure compared to physiotherapy alone as secondary prevention of lymphedema in breast cancer patients undergoing axillary lymph node dissection.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Breast cancer patients aged ≥ 18 years with an ECOG score \> 1
- Breast cancer patients with post-axillary lymph node dissection diagnosed with stage 0 and I lymphedema.
- Those who have never undergone lymphedema physiotherapy.
Exclusion criteria
- Patients with dermal backflow before axillary lymph node dissection (ALND).
- Patients with breast cancer lymphedema who are unable to undergo a 24-month follow-up at Dharmais Cancer Hospital.
- Patients with iodine allergy, severe asthma, decreased kidney function, pregnancy, or breastfeeding.
Where it is running
1 location listed.
- Dharmais National Cancer Center - Jakarta, Jakarta Special Capital Region, Indonesia